Role of urothelial cells in BCG immunotherapy for superficial bladder cancer

British Journal of Cancer

Volumn 91, Issue 4, 2004, Pages 607-612

  Bevers, R F M ^a   Kurth, K H ^b   Schamhart, D H J ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Bacillus Calmette Gu rin; Bladder cancer; Cytokine; Immunotherapy

Indexed keywords

ANTIGEN; BCG VACCINE; CYTOKINE; INTERLEUKIN 6; INTERLEUKIN 8; LIGAND; RECEPTOR;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; BACTERIUM; BLADDER CARCINOMA; BLADDER WALL; CANCER CELL; CANCER GROWTH; CANCER RECURRENCE; CELL ACTIVITY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; DRUG INSTILLATION; EPITHELIUM CELL; HOST; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOTHERAPY; INFLAMMATION; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; NONHUMAN; PHENOTYPE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY; URINALYSIS; UROTHELIUM;

EID: 4344607063     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602026     Document Type: Short Survey

References (35)

1. Alexandroff AB, Jackson AM, O'Donnell MA, James K (1999) BCG immunotherapy of bladder cancer: 20 years on. Lancet 353: 1689-1694
2. Bevers RFM, de Boer EC, Kurth K-H, Schamhart DHJ (1998) BCG-induced interleukin-6 upregulation and BCG internalization in well and poorly differentiated human bladder cancer cell lines. Eur Cytokine Network 9: 181-186
3. Bevers RFM, de Boer EC, Kurth K-H, Schamhart DHJ (2000) BCG internalization in human bladder cancer cell lines, especially with regard to cell surface-expressed fibronectin. Aktuelle Urol 31(Suppl 1): 31-34
4. Boer de EC, Somogyi L, de Ruiter GJ, de Reijke TM, Kurth KH, Schamhart DH (1997) Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer. Urol Res 25: 31-34
5. Brandau S, Riemensberger J, Jacobsen M, Kemp D, Zhao W, Zhao X, Jocham D, Ratliff TL, Böhle A (2001) NK cells are essential for the effective BCG immunotherapy. Int J Cancer 92: 697-702
6. Champetier D, Valignat C, Lopez JG, Ruffion A, Devonec M, Perrin P (2000) Intravesical BCG-therapy: comparison of side effects of Connaught (Toronto) and Pasteur (Paris) strains [Article in French]. Prog Urol 10: 542-547
7. De Boer EC, Rooijakkers SJ, Schamhart DH, Kurth KH (2003) Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response. J Urol 170: 2004-2008
8. Diehl S, Rincon M (2002) The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol 39: 531-536
9. Durek C, Brandau S, Ulmer AJ, Flad HD, Jocham D, Böhle A (1999) Bacillus-Calmette-Guérin (BCG) and 3D tumors: an in vitro model for the study of adhesion and invasion. J Urol 162: 600-605
10. Waf1-Cip1 during treatment of superficial bladder cancer. J Urol 162: 225-230
11. Hudson MA, Brown EJ, Ritchey JK, Ratliff TL (1991) Modulation of fibronectin-mediated Bacillus Calmette-Guérin attachment to murine bladder mucosa by drugs influencing the coagulation pathways. Cancer Res 51: 3726-3732
12. Ikeda N, Toida I, Iwasaki A, Kawai K, Akaza H (2002) Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Guérin (BCG): a role of BCG internalization into tumor cells. Int J Urol 9: 29-35
13. Jackson AM, Alexandroff AB, McIntyre M, Esuvaranathan K, James K, Chisholm GD (1994) Induction of ICAM 1 expression on bladder tumors by BCG immunotherapy. J Clin Pathol 47: 309-312
14. Jansson OT, Morcos E, Brundin L, Lundberg JO, Adolfsson J, Soderhall M, Wiklund NP (1998) The role of nitric oxide in bacillus Calmette-Guérin mediated anti-tumor effects in human bladder cancer. Br J Cancer 78: 588-592
15. Kärre K (1995) Express yourself or die: Peptides, MHC molecules and NK cells. Science 267: 978-979
16. Kavoussi LR, Brown EJ, Ritchey JK, Ratliff TL (1990) Fibronectin-mediated Calmette-Guérin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest 85: 62-67
17. Kawashima T, Norose Y, Watanabe Y, Enomoto Y, Narazaki H, Watari E, Tanaka S, Takahashi H, Yano I, Brenner MB, Sugita M (2003) Cutting edge: major CD8 T cell response to live bacillus Calmette-Guèrin is mediated by CD1 molecules. J Immunol 170: 5345-5348
18. Kurth KH, Bouffioux C, Sylvester R, van der Meijden AP, Oosterlinck W, Brausi M (2000) Treatment of superficial bladder tumors: achievements and needs The EORTC Genitourinary Group. Eur Urol 37(Suppl 3): 1-9
19. Lattime EC, Gomella LG, McCue P (1992) Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells. Cancer Res 52: 4286-4290
20. Lauta VM (2003) A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 97: 2440-2452
21. Levine SJ (1995) Bronchial epithelial cell-cytokine interactions in airway inflammation. J Invest Med 43: 241-249
22. Maksymowych WP, Kane KP (2000) Bacterial modulation of antigen processing and presentation. Microb Infect 2: 199-211
23. Melekos MD, Chionis H, Pantazakos A, Fokaefs E, Paranychianakis G, Dauaher H (1993) Intravesical bacillus Calmette-Guérin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule. J Urol 149: 744-748
24. Morales A, Chin JL, Ramsey EW (2001) Mycobacterial cell wall extract for the treatment of carcinoma in situ of the bladder. J Urol 166: 1633-1638
25. Nadler R, Luo Y, Zhao W, Ritchey JK, Austin JC, Cohen MB, O'Donnell MA, Ratliff TL (2003) Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumor activity. Clin Exp Immunol 131: 206-216
26. Neyrolles O, Gould K, Gares MP, Brett S, Janssen R, O'Gaora P, Herrmann JL, Prevost MC, Perret E, Thole JE, Young D (2001) Lipoprotein access to MHC class I presentation during infection of murine macrophages with live mycobacteria. J Immunol 166: 447-457
27. Ratliff TL, Palmer JO, McGarr JA, Brown EJ (1987) Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin. Cancer Res 47: 1762-1766
28. Saint F, Patard JJ, Groux Muscatelli B, Lefefre Belda MA, Gil Diez de Medina S, Abbou CC, Chopin DK (2001) Evaluation of cellular tumor rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Guérin treatment. BJU Int 88: 602-610
29. Schamhart DH, De Boer EC, Vleeming R, Kurth KH (1994) Theoretical and experimental evidence on the use of glycosaminoglycans in BCG-mediated immunotherapy of superficial bladder cancer. Semin Thromb Hemost 20: 301-309
30. Schneider B, Thanhauser A, Jocham D, Loppnow H, Vollmer E, Galle J, Flad HD, Ulmer AJ, Böhle A (1994) Specific binding of bacillus Calmette-Guérin to urothelial tumor cells in vitro. World J Urol 12: 337-344
31. Sieling PA, Ochoa MT, Jullien D, Leslie DS, Sabet S, Rosat JP, Burdick AE, Rea TH, Brenner MB, Porcelli SA, Modlin RL (2000) Evidence for human CD4+ T cells in the CD1-restricted repertoire: derivation of mycobacteria-reactive T cells from leprosy lesions. J Immunol 164: 4790-4796
32. Teppema JS, de Boer EC, Steerenberg PA, van der Meijden AP (1992) Morphological aspects of the interaction of Bacillus Calmette-Guérin with urothelial bladder cells in vivo and in vitro: relevance for antitumor activity? Urol Res 20: 219-228
33. Witjes WP, Witjes JA, Oosterhof GO, Debruyne MJ (1996) Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Tice-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. Semin Urol Oncol 14(Suppl 1): 10-16
34. Yamada H, Matsumoto S, Matsumoto T, Yamada T, Yamashita U (2000) Murine IL-2 secreting recombinant Bacillus Calmette-Guèrin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2. J Urol 164: 526-531
35. Zhao W, Schorey JS, Bong-Mastek M, Ritchey J, Brown EJ, Ratliff TL (2000) Role of a bacillus Calmette-Guérin fibronectin attachment protein in BCG-induced antitumor activity. Int J Cancer 86: 83-88